Skip to main content

Table 1 Baseline characteristics

From: Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children

 

Beclomethasone (BDP group) (N = 110)

Salbutamol (Placebo group) (N = 56)

Male, n (%)

64 (58.2)

34 (60.7)

Risk factors for asthma, n (%)

57 (51.8)

30 (53.6)

Age, yr

2.35 ± 0.81

2.29 ± 0.78

Weight, kg

15.4 ± 2.82

14.9 ± 2.74

Height, cm

97.5 ± 9.19

96.0 ± 9.61

Duration of wheezing, yr

1.59 ± 0.87

1.43 ± 0.82

Symptom-free days, %

21.4 ± 18.3

25.9 ± 21.0

Daily coughing score

1.43 ± 0.71

1.35 ± 0.80

Daily Salbutamol use, na

0.49 ± 0.48

0.42 ± 0.35

  1. Values of symptom-free days, daily coughing score and daily salbutamol use are mean of the 2-week run-in period ± SD. Beclomethasone = beclomethasone dipropionate; a number of nebulizations per day.